Diebold Nixdorf Incorporated DBD reported fourth-quarter adjusted earnings per share of 97 cents, lower than $3.02 in the year-ago period.
Quarterly sales were $988.90 million, down from $1.037 billion a year ago.
Diebold Nixdorf announced Wednesday that its board of directors has authorized a new share repurchase program, under which it may repurchase up to $100 million of common stock.
“Our team delivered strong financial performance in 2024, driven by our meaningful operational improvements, continued disciplined approach to capital allocation and balance sheet management, as well as strong free cash flow generation — the highest we have generated in nearly 10 years,” Octavio Marquez, Diebold Nixdorf president and CEO said.
“The progress we made enabled us to pay down $338 million of debt throughout the year and initiate a $100 million share repurchase program, underscoring our commitment to return significant value to our stockholders,” he added.
The company exited the quarter with cash and equivalents worth $311.3 million and inventories worth $528.1 million.
Long-term debt as of quarter end totals $927.3 million.
In 2025, the company expects flat to low single-digit revenue growth, adjusted EBITDA in the range of $470 million to $490 million, and free cash flow of $190 million to $210 million.
Outlook: Total revenue guidance expects low single-digit growth in banking and retail (constant currency), with retail picking up in the second half of 2025. There will be a 3%-4% ($115 million) negative impact from foreign exchange, and revenue is expected to be more concentrated in the second half of the year (45% in the first half, 55% in the second half).
Price Action: DBD shares are trading lower by 1.75% to $43.23 premarket at last check Wednesday.
Read Next:
Photo: Shutterstock
Market News and Data brought to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
